Home  /  Resource Library  /  Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

ASH 2020: Results of a phase II study investigating parsaclisib for treatment relapsed follicular lymphoma.